you are viewing a single comment's thread.
You are one of two types.You are either a basher, imho, or you do not use due diligence as the most fitting tool.This is an established niche pharma and had you listened to their last CC, you would have heard the analysts queries. They have now, as in the past worked well with the FDA. This is one of the applications for this drug that has blockbuster potential,The recent upgrades were based on what will happen in the future, as these applications garner approval. The next one, for which they are preparing the NDA, is even more significant.Do some due diligence, before, as a newcomer, you stick your foot in your mouth.Saliz is here to stay.